Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, Goettl VM, Tran M, Harrington BK, Rogers KA, Awan FT, Maddocks K, Andritsos L, Lehman AM, Sampath D, Lapalombella R, Eathiraj S, Abbadessa G, Schwartz B, Johnson AJ, Byrd JC, Woyach JA.

Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.

PMID:
30093506
2.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Reiff SD, Muhowski EM, Guinn D, Lehman A, Fabian CA, Cheney C, Mantel R, Smith L, Johnson AJ, Young WB, Johnson AR, Liu L, Byrd JC, Woyach JA.

Blood. 2018 Sep 6;132(10):1039-1049. doi: 10.1182/blood-2017-10-809020. Epub 2018 Jul 17.

PMID:
30018078
3.

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients.

Agrawal AA, Seiler M, Brinton LT, Mantel R, Lapalombella R, Woyach JA, Johnson AJ, Zhu P, Warmuth M, Yu L, Byrd JC, Smith PG, Blachly JS, Buonamici S.

Blood Adv. 2017 Jun 14;1(15):995-1000. doi: 10.1182/bloodadvances.2017007062. eCollection 2017 Jun 27.

4.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC.

J Clin Oncol. 2017 May 1;35(13):1437-1443. doi: 10.1200/JCO.2016.70.2282. Epub 2017 Feb 13.

5.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Mantel R, Smith LL, McClanahan F, Harrington BK, Colomer D, Covey T, Byrd JC, Izumi R, Kaptein A, Ulrich R, Johnson AJ, Lannutti BJ, Wiestner A, Woyach JA.

Clin Cancer Res. 2017 Jun 1;23(11):2831-2841. doi: 10.1158/1078-0432.CCR-16-0463. Epub 2016 Nov 30.

6.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D.

Blood. 2016 Dec 29;128(26):3101-3112. doi: 10.1182/blood-2016-07-727750. Epub 2016 Oct 17.

7.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.

JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.

8.

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, Williams K, Johnson AJ, Lehman AM, Byrd JC, Woyach JA, Lapalombella R.

Blood. 2015 May 14;125(20):3128-32. doi: 10.1182/blood-2015-01-621391. Epub 2015 Apr 2.

9.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC.

Blood. 2014 Mar 20;123(12):1810-7. doi: 10.1182/blood-2013-09-527853. Epub 2014 Jan 10.

10.

Automated analysis of antepartum fetal heart rate in relation to fetal rest-activity states: a longitudinal study of uncomplicated pregnancies using the Sonicaid System 8000.

Mantel R, Van Geijn HP, Ververs IA, Colenbrander GJ, Kostense PJ.

Eur J Obstet Gynecol Reprod Biol. 1997 Jan;71(1):41-51.

PMID:
9031959
11.

Periodic forcing of spiral waves in excitable media.

Mantel RM, Barkley D.

Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1996 Nov;54(5):4791-4802. No abstract available.

PMID:
9965659
12.

Fetal heart rate patterns and chronic exposure to antiepileptic drugs.

Swartjes JM, van Geijn HP, Meinardi H, Mantel R.

Epilepsia. 1992 Jul-Aug;33(4):721-8.

PMID:
1628590
13.

Fetal motility and chronic exposure to antiepileptic drugs.

Swartjes JM, van Geijn HP, Meinardi H, van Woerden EE, Mantel R.

Eur J Obstet Gynecol Reprod Biol. 1992 Jun 16;45(1):37-45.

PMID:
1618360
14.

Quantitated fetal heart rhythm at 20, 32 and 38 weeks of gestation and dependence on rest-activity patterns.

Swartjes JM, van Geijn HP, Mantel R, Schoemaker HC.

Early Hum Dev. 1992 Jan;28(1):27-36.

PMID:
1582373
15.

A comparative clinical study of fetal phono- and movement-sensors from Amsterdam, Cambridge and Edinburgh.

Goovaerts HG, Cohen D, Dripps JH, Mantel R, Mooney P, Jongsma HW, Dalton KJ, van Geijn HP.

J Biomed Eng. 1991 Nov;13(6):495-9.

PMID:
1770810
16.

Automated analysis of near-term antepartum fetal heart rate in relation to fetal behavioral states: the Sonicaid System 8000.

Mantel R, van Geijn HP, Ververs IA, Copray FJ.

Am J Obstet Gynecol. 1991 Jul;165(1):57-65.

PMID:
1853916
17.

Recording fetal breathing movements with a passive transducer based on an inductive principle.

Goovaerts HG, van Geijn HP, Rompelman O, Mantel R, Swartjes JM.

Med Biol Eng Comput. 1991 Jul;29(4):358-64.

PMID:
1787750
18.

Duration, amplitude and shape of accelerations in relation to fetal body movements in behavioral state 2F.

van Woerden EE, van Geijn HP, Mantel R, Swartjes JM.

J Perinat Med. 1991;19(1-2):73-80.

PMID:
1870060
19.

Coincidence of behavioural state parameters in the human fetus at three gestational ages.

Swartjes JM, van Geijn HP, Mantel R, van Woerden EE, Schoemaker HC.

Early Hum Dev. 1990 Aug;23(2):75-83.

PMID:
2257791
20.

Computer analysis of antepartum fetal heart rate: 2. Detection of accelerations and decelerations.

Mantel R, van Geijn HP, Caron FJ, Swartjes JM, van Woerden EE, Jongsma HW.

Int J Biomed Comput. 1990 May;25(4):273-86.

PMID:
2194980
21.

Computer analysis of antepartum fetal heart rate: 1. Baseline determination.

Mantel R, van Geijn HP, Caron FJ, Swartjes JM, van Woerden EE, Jongsma HW.

Int J Biomed Comput. 1990 May;25(4):261-72.

PMID:
2194979
22.

Spectral analysis of fetal heart rhythm in relation to fetal regular mouthing.

van Woerden EE, van Geijn HP, Caron FJ, Mantel R.

Int J Biomed Comput. 1990 May;25(4):253-60.

PMID:
2194978
23.

Automated assignment of behavioural states in the human near term fetus.

van Woerden EE, van Geijn HP, Caron FJ, Swartjes JM, Mantel R, Arts NF.

Early Hum Dev. 1989 May;19(2):137-46.

PMID:
2737104
24.

Fetal hiccups; characteristics and relation to fetal heart rate.

van Woerden EE, van Geijn HP, Caron FJ, Mantel R, Swartjes JM, Arts NF.

Eur J Obstet Gynecol Reprod Biol. 1989 Mar;30(3):209-16.

PMID:
2653889
25.

Computerized assessment of fetal behavioral states.

Caron FJ, van Geijn HP, van Woerden EE, Swartjes JM, Mantel R.

J Perinat Med. 1988;16(4):365-72.

PMID:
3221295
26.

Effects of adrenaline, angiotensin and calcium on spontaneously active and potassium-depolarized rat portal veins.

Mantel R, Taquini AC Jr, Savino EA.

Arch Int Physiol Biochim. 1975 May;83(2):211-9.

PMID:
54053

Supplemental Content

Loading ...
Support Center